Ultimovacs AB
Pioneering off-the-shelf TCR-NK cell therapies to cure solid cancers.
Oversigt
- 0
- Medarbejdere
- 5–10mio SEK
- Omsætning
- 2018
- Grundlagt
Nøglebeslutningstagere
Namir Hassan
CEO
Beskrivelse
Zelluna is a biotechnology company dedicated to pioneering novel cell therapies for the treatment of cancer patients. Their core mission is to eliminate solid cancers by developing T cell receptor (TCR) guided natural killer (NK) cell therapies, known as TCR-NK. This proprietary platform aims to ove...
Tags
Nøgleord
Virksomhedsoplysninger
- Branche
- Bioteknisk forskning och utveckling
- Juridisk form
- Aktiebolag
- Momsnummer
- SE559144316201
Beslutningstagere
1 kontakter i FunnelfeedrNamir Hassan
CEO
Lignende virksomheder
20 lignende virksomheder i Funnelfeedr
ZELLUNA IMMUNOTHERAPY AS
9 medarbejderePioneering TCR-NK cell therapies to eliminate solid cancers safely.
ZELLUNA ASA
7 medarbejderePioneering TCR-NK cell therapies to eliminate solid cancers effectively.
CuraCell TX AB
5 medarbejdereEuropean biotech developing personalized T-cell therapies for solid cancer tumors.
CANTARGIA AB
20–49 medarbejdereDeveloping antibody-based drugs targeting IL1RAP for serious diseases.
BIO INVENTION AS
Clinical-stage company developing novel immuno-oncology antibody therapeutics for cancer.
Udforsk mere
Spørgsmål om Ultimovacs AB
Vil du se Funnelfeedr i aktion?
Book en gratis demo og opdag, hvordan Funnelfeedr hjælper dig med at finde og konvertere dine ideelle kunder.
Book en demo